1stOncology™: Cancer Intelligence Service – Page 132 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

On January 4, 2026 Insilico Medicine ("Insilico"), a world-leading artificial intelligence (AI)-driven drug discovery company, reported a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and developing novel therapeutics for challenging targets in the oncology space by leveraging Insilico’s proprietary AI platform, Pharma.AI.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Under the agreement, Insilico will be eligible to receive up to US$32 million in upfront and near-term R&D payments and will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria, while Servier will share the R&D expenses and lead clinical validation and commercialization processes.

"This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform", said Christophe Thurieau, Executive Director Research at Servier.

"I am excited to see the collaboration—it is yet another strong acknowledgment of our AI capabilities and R&D expertise", said Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico Medicine. "As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development."

Insilico has extensive experience in AI-driven oncology drug discovery and development. The company has established a robust oncology pipeline that targets multiple cancer indications, leveraging both moderately novel and well-established mechanisms. Among its most promising assets, the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412 are both undergoing global, multicenter Phase I clinical trials. Additionally, four other oncology programs have been fully or partially out-licensed to partners, with Phase I clinical trials actively in progress.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

(Press release, Insilico Medicine, JAN 4, 2026, View Source [SID1234661696])

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

On January 2, 2026 Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, reported the filing of two U.S. provisional patent applications that significantly expand the Company’s intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.

The first provisional patent application, titled covering the topical treatment of radiation-induced skin toxicity in oncology patients.

The second provisional patent application, titled addressing dermatologic toxicities associated with emerging targeted cancer therapies, including second and third menin inhibitors.

Together, these dual filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents. As cancer treatments become more effective and patients remain on therapy longer, managing treatment-limiting skin toxicities has become a critical and growing unmet need in oncology care.

Radiotherapy-induced dermatitis and dermatologic adverse effects from targeted oncology therapies frequently result in pain, inflammation, severe pruritus, infection risk, reduced quality of life, and treatment interruption or discontinuation, which can negatively impact patient outcomes. Despite their prevalence, current treatment options remain largely supportive, with few mechanism-driven therapies designed to address the underlying biological drivers of these conditions.

Hoth’s patent filings seek to protect the use of HT-001, a receptor antagonist with a well-established pharmacologic profile, to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. The Company believes this approach may represent a novel and potentially first-in-class strategy within the rapidly expanding oncology supportive-care and oncodermatology markets.

"These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care," said Robb Knie of Hoth Therapeutics. "As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value."

The Company believes these provisional patents support the development of a scalable oncology-adjacent platform with potential applications across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders, while leveraging an established compound in novel therapeutic contexts, formulations, and routes of administration. The filings also provide flexibility to pursue additional preclinical development, formulation optimization, and future U.S. and international patent protection.

Hoth Therapeutics continues to execute its strategy of building a diversified, IP-centric development portfolio focused on large, underserved markets, with an emphasis on therapies designed to improve patient outcomes and quality of life.

(Press release, Hoth Therapeutics, JAN 2, 2026, View Source [SID1234661689])

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On January 2, 2026 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, reported that on January 1, 2026, it awarded inducement grants to two new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

The inducement grants consisted of time-based restricted stock units ("RSUs") for an aggregate of 22,800 shares of Intellia’s common stock, with one-third of such RSUs vesting annually over three years. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.

All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).

(Press release, Intellia, JAN 2, 2026, View Source [SID1234661687])

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

On January 2, 2026 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at View Source To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.

(Press release, Regeneron, JAN 2, 2026, View Source [SID1234661686])

Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference

On January 2, 2026 Bristol Myers Squibb (NYSE: BMY) reported that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026.

The company’s presentation and participation in a fireside chat will begin at 7:30 a.m. PST/10:30 a.m. ET.

The event will be webcast simultaneously at View Source, with materials related to the presentation available at the start of the live webcast. A replay and archived edition of the presentation will be available following the conclusion of the event.

(Press release, Bristol-Myers Squibb, JAN 2, 2026, View Source;Morgans-44th-Annual-Healthcare-Conference/default.aspx [SID1234661685])